Hyperphosphatemia Drugs Market Rapidly Develop, Top Manufacturers Forecast to 2027: Keryx Biopharmaceuticals, Astellas Pharma, Japan Tobacco, Ardelyx
The “Hyperphosphatemia Drugs Market” report provides a quick description about market status, size, companies share, growth, opportunities and upcoming trends. This report includes the corporate profile, values that the challenges and drivers & restraints that have a serious impact on the industry analysis. The information within the report that help form the longer term projections during the forecast year. The up so far analysis to assists in understanding of the changing competitive analysis. Additionally, the market strategies including moderate growth during the years.
The research on Hyperphosphatemia Drugs market scenario which will affect the overview the forecast period, including as opportunities, prime challenges, and current/future trends. To supply an in-depth analysis of all Hyperphosphatemia Drugs regions included within the report into sections to supply a comprehensive competitive analysis.
Some of the leading manufacturers and suppliers of the Hyperphosphatemia Drugs market are Keryx Biopharmaceuticals, Inc., Astellas Pharma Inc., Japan Tobacco Inc., Ardelyx, Inc., OPKO Health, Inc., BioLink Life Sciences, Inc., F Hoffmann-La Roche AG, Lupin Limited, Fresenius Medical Care, and Vifor Pharma Group.
Hyperphosphatemia is a condition that occurs when the blood contains too much phosphate or phosphorous. Phosphate is a substance present in the human body that contains the mineral phosphorous. The mineral phosphorus is essential for the growth of teeth and bones, as well as the conversion of food into energy for the body.
Phosphate can be found in large levels in the teeth, bones, and inside cells, as well as in very minute amounts in the blood. The kidneys are responsible for controlling the body’s phosphate levels. However, different complications/diseases cause renal damage, resulting in a chronically high phosphate level in the blood.
Hyperphosphatemia is particularly common in persons with chronic kidney disease, especially in those who are towards the end of their lives. Hyperphosphatemia can also be caused by diabetic ketoacidosis, uncontrolled diabetes, high vitamin D levels, and low parathyroid hormone levels, among other things.
Buy This Complete A Business Report With Flat US $2000 Off @
The global hyperphosphatemia medications market is likely to rise in the near future due to increased launches and approvals of novel drugs in major areas. For example, in 2016, Astellas Pharma Inc. received marketing approval for its Kiklin Granules 86.2%, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission for new drug Fexeric (R) (ferric citrate coordination complex), indicated for the treatment of hyperphosphatemia in adults with chronic kidney disease.
Keryx Biopharmaceuticals, Inc. got FDA approval for the medication Ferric Citrate (previously known as Zerenex) in 2014, a new, oral iron-based therapy for dialysis patients with hyperphosphatemia. Keryx Biopharmaceuticals, Inc. released Auryxia (ferric citrate) tablets in 2014. Auryxia is an iron-based phosphate binder that is easily absorbed. Indicated for the treatment of hyperphosphatemia in chronic kidney disease.
The hyperphosphatemia medications market is predicted to flourish in a favourable environment as a result of strategic mergers and acquisitions by leading industry competitors. For example, in 2013, OPKO Health, Inc. acquired Canada-based Cytochroma Inc., with this strategic acquisition OPKO Health, Inc. has expanded its portfolio with Cytochroma Inc.’s Alpharen, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients.
Moreover, persons with chronic renal illness are at a significant risk of having hyperphosphatemia. As a result, rising prevalence of chronic renal disease is predicted to increase the risk of hyperphosphatemia in the population, driving up demand for hyperphosphatemia pharmaceuticals and propelling the hyperphosphatemia drugs market forward.
For example, according to the data published in National Chronic Kidney Disease Fact Sheet 2017, an estimated 30 million people or 15% of U.S. adults are suffering from chronic kidney disease. Chronic kidney diseases were estimated to be more common in Women (16%) as compared to men (13%).
Main points in Hyperphosphatemia Drugs Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Hyperphosphatemia Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Hyperphosphatemia Drugs Industry Impact
Chapter 2 Global Hyperphosphatemia Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Hyperphosphatemia Drugs (Volume and Value) by Type
2.3 Global Hyperphosphatemia Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Hyperphosphatemia Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Hyperphosphatemia Drugs Market Analysis
Chapter 6 East Asia Hyperphosphatemia Drugs Market Analysis
Chapter 7 Europe Hyperphosphatemia Drugs Market Analysis
Chapter 8 South Asia Hyperphosphatemia Drugs Market Analysis
Chapter 9 Southeast Asia Hyperphosphatemia Drugs Market Analysis
Chapter 10 Middle East Hyperphosphatemia Drugs Market Analysis
Chapter 11 Africa Hyperphosphatemia Drugs Market Analysis
Chapter 12 Oceania Hyperphosphatemia Drugs Market Analysis
Chapter 13 South America Hyperphosphatemia Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Hyperphosphatemia Drugs Business
Chapter 15 Global Hyperphosphatemia Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Lifestyle Drugs Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2021-2028
Anti-malarial Drugs Market, by Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Iloprost Drugs Market, By Route of Administration (Intravenous, and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire